DE19624659A1 - Neue Pyridylalken- und Pyridylalkinsäureamide - Google Patents

Neue Pyridylalken- und Pyridylalkinsäureamide

Info

Publication number
DE19624659A1
DE19624659A1 DE19624659A DE19624659A DE19624659A1 DE 19624659 A1 DE19624659 A1 DE 19624659A1 DE 19624659 A DE19624659 A DE 19624659A DE 19624659 A DE19624659 A DE 19624659A DE 19624659 A1 DE19624659 A1 DE 19624659A1
Authority
DE
Germany
Prior art keywords
alkyl
hydrogen
hydroxy
ring
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19624659A
Other languages
German (de)
English (en)
Inventor
Elfi Biedermann
Max Dr Hasmann
Roland Dr Loeser
Benno Dr Rattel
Friedemann Dr Reiter
Barbara Schein
Klaus Prof Dr Seibel
Klaus Dr Vogt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Deutschland GmbH
Original Assignee
Klinge Pharma GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinge Pharma GmbH and Co filed Critical Klinge Pharma GmbH and Co
Priority to DE19624659A priority Critical patent/DE19624659A1/de
Priority to ZA9705437A priority patent/ZA975437B/xx
Priority to PCT/EP1997/003245 priority patent/WO1997048696A1/en
Priority to ES97928261T priority patent/ES2179351T3/es
Priority to AT97928261T priority patent/ATE224888T1/de
Priority to DK97928261T priority patent/DK0923570T3/da
Priority to PT97928261T priority patent/PT923570E/pt
Priority to TR1998/02651T priority patent/TR199802651T2/xx
Priority to EP97928261A priority patent/EP0923570B1/en
Priority to HU9903766A priority patent/HU225715B1/hu
Priority to IL12735297A priority patent/IL127352A/xx
Priority to AU32625/97A priority patent/AU736206B2/en
Priority to CA002257448A priority patent/CA2257448C/en
Priority to CNA2004100325866A priority patent/CN1546472A/zh
Priority to RU99101069/04A priority patent/RU2200734C2/ru
Priority to CZ19984093A priority patent/CZ291791B6/cs
Priority to HK99106092.6A priority patent/HK1021974B/en
Priority to JP50231898A priority patent/JP4225572B2/ja
Priority to BRPI9709823-0B1A priority patent/BR9709823B1/pt
Priority to DE69715888T priority patent/DE69715888T2/de
Priority to CNB971974241A priority patent/CN1152032C/zh
Publication of DE19624659A1 publication Critical patent/DE19624659A1/de
Priority to US10/213,952 priority patent/US7241745B2/en
Priority to US11/635,157 priority patent/US20070219197A1/en
Priority to US11/678,980 priority patent/US20070142377A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
DE19624659A 1996-06-20 1996-06-20 Neue Pyridylalken- und Pyridylalkinsäureamide Ceased DE19624659A1 (de)

Priority Applications (24)

Application Number Priority Date Filing Date Title
DE19624659A DE19624659A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalken- und Pyridylalkinsäureamide
ZA9705437A ZA975437B (en) 1996-06-20 1997-06-19 New pyridyl alkene and pyridyl alkine acid amides.
AU32625/97A AU736206B2 (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives
CNA2004100325866A CN1546472A (zh) 1996-06-20 1997-06-20 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂
AT97928261T ATE224888T1 (de) 1996-06-20 1997-06-20 Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
DK97928261T DK0923570T3 (da) 1996-06-20 1997-06-20 Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler
PT97928261T PT923570E (pt) 1996-06-20 1997-06-20 Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos
TR1998/02651T TR199802651T2 (xx) 1996-06-20 1997-06-20 Piridilalken, Piridil-Alkin Asit Amidleri
EP97928261A EP0923570B1 (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives
HU9903766A HU225715B1 (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine- acid amides, use of them as cytostatics and immunosuppressives, process for their preparation and pharmaceuticals containing the same
IL12735297A IL127352A (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine-acid amides and pharmaceutical compositions containing them
PCT/EP1997/003245 WO1997048696A1 (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives
CA002257448A CA2257448C (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine-acid amides as cytostatics and immunosuppressives
ES97928261T ES2179351T3 (es) 1996-06-20 1997-06-20 Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
RU99101069/04A RU2200734C2 (ru) 1996-06-20 1997-06-20 Амиды пиридилалкеновых и пиридилалкиновых кислот, способы их получения, фармацевтическая композиция на их основе и способ ее получения
CZ19984093A CZ291791B6 (cs) 1996-06-20 1997-06-20 Amidy pyridylalkenové a pyridylalkinové kyseliny jako cytostatika a imunosupresiva
HK99106092.6A HK1021974B (en) 1996-06-20 1997-06-20 Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives
JP50231898A JP4225572B2 (ja) 1996-06-20 1997-06-20 細胞増殖抑制剤および免疫抑制剤としてのピリジルアルケン―およびピリジルアルキン―酸アミド類
BRPI9709823-0B1A BR9709823B1 (pt) 1996-06-20 1997-06-20 "compostos de amidas de ácido alqueno piridílico e alquino piridílico, métodos de preparação e uso dos mesmos, bem como medicamento".
DE69715888T DE69715888T2 (de) 1996-06-20 1997-06-20 Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
CNB971974241A CN1152032C (zh) 1996-06-20 1997-06-20 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂
US10/213,952 US7241745B2 (en) 1996-06-20 2002-08-05 Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives
US11/635,157 US20070219197A1 (en) 1996-06-20 2006-12-07 Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives
US11/678,980 US20070142377A1 (en) 1996-06-20 2007-02-26 Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19624659A DE19624659A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalken- und Pyridylalkinsäureamide

Publications (1)

Publication Number Publication Date
DE19624659A1 true DE19624659A1 (de) 1998-01-08

Family

ID=7797501

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19624659A Ceased DE19624659A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalken- und Pyridylalkinsäureamide
DE69715888T Expired - Lifetime DE69715888T2 (de) 1996-06-20 1997-06-20 Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69715888T Expired - Lifetime DE69715888T2 (de) 1996-06-20 1997-06-20 Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel

Country Status (19)

Country Link
US (3) US7241745B2 (enExample)
EP (1) EP0923570B1 (enExample)
JP (1) JP4225572B2 (enExample)
CN (2) CN1546472A (enExample)
AT (1) ATE224888T1 (enExample)
AU (1) AU736206B2 (enExample)
BR (1) BR9709823B1 (enExample)
CA (1) CA2257448C (enExample)
CZ (1) CZ291791B6 (enExample)
DE (2) DE19624659A1 (enExample)
DK (1) DK0923570T3 (enExample)
ES (1) ES2179351T3 (enExample)
HU (1) HU225715B1 (enExample)
IL (1) IL127352A (enExample)
PT (1) PT923570E (enExample)
RU (1) RU2200734C2 (enExample)
TR (1) TR199802651T2 (enExample)
WO (1) WO1997048696A1 (enExample)
ZA (1) ZA975437B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
CZ302015B6 (cs) * 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
EP3279192A1 (en) * 2016-08-05 2018-02-07 Centre Hospitalier Universitaire Vaudois (CHUV) Piperidine derivatives for use in the treatment of pancreatic cancer

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19756261A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756236A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
JP3475177B2 (ja) * 1998-11-17 2003-12-08 エフ．ホフマン−ラ ロシュ アーゲー ４−アロイルピペリジンｃｃｒ−３受容体拮抗剤ｉｉｉ
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6432432B1 (en) 1999-03-05 2002-08-13 Arch Chemicals, Inc. Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
AU2002367773A1 (en) 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
US20110045065A1 (en) * 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
EP2318369A1 (en) 2008-06-24 2011-05-11 TopoTarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
AU2009286604B2 (en) 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
US8426446B2 (en) 2009-05-12 2013-04-23 Beijing Shiqiao Biopharm Co. Ltd. Acrylamide derivative and use thereof in manufacture of medicament
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
CN103384668B (zh) 2010-09-03 2017-05-31 福马Tm有限责任公司 用于抑制nampt的化合物和组合物
RU2016116533A (ru) 2010-09-03 2018-11-30 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
CA2810049A1 (en) 2010-09-03 2012-03-08 Forma Tm, Llc Guanidine compounds and compositions for the inhibition of nampt
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
BR112013006030B1 (pt) * 2010-09-29 2020-03-17 Intervet International B.V. Composto e sais ou n-óxidos farmaceuticamente aceitáveis, e, uso do composto
AR083855A1 (es) 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
WO2012067963A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors
RU2616612C2 (ru) * 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
IN2013MN02014A (enExample) 2011-05-09 2015-06-12 Forma Tm Llc
TWI574957B (zh) 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
JP2015516436A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
US9187472B2 (en) 2012-05-11 2015-11-17 Abbvie Inc. NAMPT inhibitors
JP2015520752A (ja) 2012-05-11 2015-07-23 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体
CA2870566A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Thiazolecarboxamide derivatives for use as nampt inhibitors
MY170437A (en) 2012-06-19 2019-07-31 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US9938258B2 (en) 2012-11-29 2018-04-10 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3010892T3 (en) 2013-06-21 2019-04-15 Karyopharm Therapeutics Inc 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF
CN108440515B (zh) 2013-07-03 2022-05-03 卡尔约药物治疗公司 取代的苯并呋喃基和苯并噁唑基化合物及其用途
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
WO2015054060A1 (en) * 2013-10-09 2015-04-16 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
AU2015293534A1 (en) 2014-07-23 2017-02-02 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as NAMPT inhibitors
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN104447486B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 二烯氟代金刚烷类化合物、其制备方法和用途
CN104447483B (zh) * 2015-01-13 2016-07-27 佛山市赛维斯医药科技有限公司 含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
CN104447484B (zh) * 2015-01-13 2016-06-08 佛山市赛维斯医药科技有限公司 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
TW201720802A (zh) * 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
PL3419628T3 (pl) 2016-02-26 2021-05-31 Debiopharm International Sa Lek do leczenia zakażeń stopy cukrzycowej
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
CN107827897A (zh) * 2017-10-23 2018-03-23 青岛大学 一种手性七元螺环吲哚酮类化合物的合成方法
WO2019149637A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN108558840B (zh) * 2018-06-04 2020-11-06 上海交通大学 水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
HRP20230437T1 (hr) 2019-02-14 2023-07-07 Debiopharm International S.A. Formulacija afabicina, postupak izrade iste
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
JP7690470B2 (ja) 2019-11-06 2025-06-10 リメディー プラン，インコーポレーテッド がん幹細胞を標的化するがん治療
CA3217380A1 (en) 2021-05-13 2022-11-17 Yushma Bhurruth-Alcor Nampt inhibitors and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283541A (en) * 1980-05-27 1981-08-11 Usv Pharmaceutical Corporation Pyridylacyl-hydroxamates
NL8005133A (nl) 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
US5326772A (en) * 1984-09-28 1994-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Diaryl compounds for their use
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3641822A1 (de) 1986-12-06 1988-06-16 Goedecke Ag Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase
JPS63179869A (ja) 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
AU638205B2 (en) 1988-02-19 1993-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
US5125957A (en) * 1989-11-01 1992-06-30 Sumitomo Chemical Company, Limited Pyrimidine derivatives
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
CA2080127A1 (en) 1990-04-10 1991-10-11 Peter Zimmermann Pyridines as medicaments
WO1991015485A1 (de) 1990-04-10 1991-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridinester
DE4020570A1 (de) 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
ATE119774T1 (de) 1990-07-30 1995-04-15 Takeda Chemical Industries Ltd Imidazopyridinderivate und ihre verwendung.
EP0479601B1 (en) 1990-10-05 1999-12-15 Ajinomoto Co., Inc. Piperidine derivatives and their use as antiarrhythmic agents
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69209576T4 (de) 1991-05-10 1997-01-30 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
US5208247A (en) 1991-08-01 1993-05-04 American Cyanamid Company Pyridinium compounds which are useful as antagonists of platelet activating factor
EP0548883A1 (de) 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
AU3171493A (en) 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
ATE210652T1 (de) 1993-10-15 2001-12-15 Schering Corp Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
ES2164717T3 (es) 1993-10-15 2002-03-01 Schering Corp Compuestos triciclicos de sulfonamida utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
WO1995024894A2 (en) 1994-03-14 1995-09-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
FR2738245B1 (fr) 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302015B6 (cs) * 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
WO2003080054A1 (en) * 2002-03-27 2003-10-02 Fujisawa Deutschland Gmbh Use of pyridyl amides as inhibitors of angiogenesis
EP3279192A1 (en) * 2016-08-05 2018-02-07 Centre Hospitalier Universitaire Vaudois (CHUV) Piperidine derivatives for use in the treatment of pancreatic cancer
WO2018024907A1 (en) * 2016-08-05 2018-02-08 Centre Hospitalier Universitaire Vaudois Chuv Piperidine derivatives for use in the treatment of pancreatic cancer
US10894785B2 (en) 2016-08-05 2021-01-19 Centre Hospitalier Universitaire Vaudois Chuv Piperidine derivatives for use in the treatment of pancreatic cancer

Also Published As

Publication number Publication date
CZ409398A3 (cs) 1999-05-12
IL127352A (en) 2003-10-31
DE69715888T2 (de) 2003-07-31
CN1152032C (zh) 2004-06-02
RU2200734C2 (ru) 2003-03-20
US7241745B2 (en) 2007-07-10
US20070219197A1 (en) 2007-09-20
BR9709823B1 (pt) 2013-09-17
HUP9903766A2 (en) 2000-09-28
CZ291791B6 (cs) 2003-05-14
PT923570E (pt) 2002-12-31
HU225715B1 (en) 2007-07-30
BR9709823A (pt) 1999-08-10
EP0923570A1 (en) 1999-06-23
AU3262597A (en) 1998-01-07
JP2000516913A (ja) 2000-12-19
ES2179351T3 (es) 2003-01-16
CN1546472A (zh) 2004-11-17
ZA975437B (en) 1998-02-10
JP4225572B2 (ja) 2009-02-18
US20070142377A1 (en) 2007-06-21
US20030162972A1 (en) 2003-08-28
WO1997048696A1 (en) 1997-12-24
CN1228777A (zh) 1999-09-15
HUP9903766A3 (en) 2000-12-28
IL127352A0 (en) 1999-10-28
ATE224888T1 (de) 2002-10-15
EP0923570B1 (en) 2002-09-25
HK1021974A1 (en) 2000-07-21
DK0923570T3 (da) 2003-01-20
CA2257448A1 (en) 1997-12-24
DE69715888D1 (de) 2002-10-31
AU736206B2 (en) 2001-07-26
TR199802651T2 (xx) 1999-04-21
CA2257448C (en) 2008-08-19

Similar Documents

Publication Publication Date Title
DE69831877T2 (de) Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide
DE19624659A1 (de) Neue Pyridylalken- und Pyridylalkinsäureamide
DE69834269T2 (de) Piperidinylsubstituierte pyridylalkan-, -alken- und -alkincarbonsäuren als cytostatika und immunsuppressiva
DE69715861T2 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
DE69830855T2 (de) Aryl-substituierte pyridylalkan-, alken-, und alkin- carboxamidderivate, verwendbar als zytostatische und immunosuppressive mittel
DE19624704A1 (de) Neue Pyridylalkansäureamide
DE19756212A1 (de) Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
KR100478405B1 (ko) 세포분열억제제및면역억제제로서의피리딜알켄-및피리딜알킨-산아미드
HK1021974B (en) Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection